Lanreotide Autogel demonstrates long-term efficacy and safety in acromegalic patients.
Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients
Abstract
Lanreotide Autogel (60, 90, or 120 mg) showed long-term efficacy and safety in acromegalic patients, including those previously treated with somatostatin analogues.